SCHEMBL577665

SCHEMBL577665

CC(C)Cc1ccc(C(C)C(=O)NN)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM1 P11229 1/20 0.73
PDE4A P27815 1/20 0.73
CXCR1 P25024 5/20 0.71
CXCR2 P25025 5/20 0.71
EPHX1 P07099 1/20 0.67
PTGS1 P23219 3/20 0.64
PTGS2 P35354 3/20 0.64
LMNA P02545 2/20 0.64
CYP2C9 P11712 2/20 0.64
AKR1C3 P42330 2/20 0.64
ALB P02768 1/20 0.64
ESR1 P03372 1/20 0.64
ALOX5 P09917 1/20 0.64
RARB P10826 1/20 0.64
ADRB3 P13945 1/20 0.64
NFKB1 P19838 1/20 0.64
HTR2A P28223 1/20 0.64
NR1I3 Q14994 1/20 0.64
SLC22A6 Q4U2R8 1/20 0.64
CXCL8 P10145 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30465076 1.00 CHRM1 (0.73) CHRM1PDE4ACXCR1CXCR2EPHX1
SCHEMBL3147555 0.84 CHRM1 (0.75) CHRM1PDE4ACXCR1CXCR2EPHX1
SCHEMBL31006096 0.84 CHRM1 (0.75) CHRM1PDE4ACXCR1CXCR2EPHX1
Ibuproxam SCHEMBL10428212 0.84 CHRM1 (1.00) CHRM1PDE4ACXCR1CXCR2EPHX1
Ibuproxam SCHEMBL8722617 0.84 CHRM1 (1.00) CHRM1PDE4ACXCR1CXCR2EPHX1
SCHEMBL19953817 0.84 CHRM1 (0.75) CHRM1PDE4ACXCR1CXCR2EPHX1
Ibuproxam SCHEMBL24896 0.84 CHRM1 (1.00) CHRM1PDE4ACXCR1CXCR2EPHX1
SCHEMBL3142734 0.84 CHRM1 (0.75) CHRM1PDE4ACXCR1CXCR2EPHX1
SCHEMBL1820667 0.83 CHRM1 (0.69) CHRM1PDE4ACXCR1CXCR2EPHX1
SCHEMBL13952025 0.83 CXCR1 (1.00) CHRM1PDE4ACXCR1CXCR2EPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250066289-A1 BIGUANIDE DERIVATIVE OF IBUPROFEN AND PROCESS OF PREPARATION THEREOF BVDU'S POONA COLLEGE OF PHARMACY (IN) 2025-02-27 US claimed
US-20250066289-A1 BIGUANIDE DERIVATIVE OF IBUPROFEN AND PROCESS OF PREPARATION THEREOF BVDU'S POONA COLLEGE OF PHARMACY (IN) 2025-02-27 US disclosed
US-12234205-B1 Sulfonylhydrazide derivatives as anticancer agents KING SAUD UNIVERSITY (SA) 2025-02-25 US disclosed
CN-116178444-A Bivalent platinum complex and derivative thereof, preparation method, pharmaceutical composition and application 东南大学 2023-05-30 CN disclosed
CN-114835656-A 1,3, 4-oxadiazole ethyl acetate and synthesis method thereof 天津中医药大学 2022-08-02 CN disclosed
US-20120115817-A1 PHTHALIMIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY COMPOUNDS AND/OR TNF-ALPHA MODULATORS, METHOD FOR PRODUCING SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USES THEREOF FOR THE TREATMENT OF INFLAMMATORY DISEASES EMS S.A. (BR) 2012-05-10 US disclosed
US-20120115817-A1 PHTHALIMIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY COMPOUNDS AND/OR TNF-ALPHA MODULATORS, METHOD FOR PRODUCING SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USES THEREOF FOR THE TREATMENT OF INFLAMMATORY DISEASES EMS S.A. (BR) 2012-05-10 US disclosed
US-20120115817-A1 PHTHALIMIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY COMPOUNDS AND/OR TNF-ALPHA MODULATORS, METHOD FOR PRODUCING SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USES THEREOF FOR THE TREATMENT OF INFLAMMATORY DISEASES EMS S.A. (BR) 2012-05-10 US disclosed
EP-2418200-A1 PHTHALIMIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY COMPOUNDS AND/OR TNF- MODULATORS, METHOD FOR PRODUCING SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USES THEREOF FOR THE TREATMENT OF INFLAMMATORY DISEASES EMS S. A. (BR) 2012-02-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12234205-B1 Sulfonylhydrazide derivatives as anticancer agents FAAH, FAAH2, ABCC4 CHRM1 4885/4885PDE4A 1901/4885CXCR1 3654/4885
US-20250066289-A1 BIGUANIDE DERIVATIVE OF IBUPROFEN AND PROCESS OF PREPARATION THEREOF SLC5A2, MYD88, MB CHRM1 4353/4885PDE4A 1272/4885CXCR1 3071/4885
US-20120115817-A1 PHTHALIMIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY COMPOUNDS AND/OR TNF-ALPHA MODULATORS, METHOD FOR PRODUCING SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USES THEREOF FOR THE TREATMENT OF INFLAMMATORY DISEASES TNF, PER2, CRY1 CHRM1 1629/4885PDE4A 340/4885CXCR1 2074/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.